{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:20:47Z","timestamp":1794244847483,"version":"4.9.0"},"reference-count":44,"publisher":"Society of Nuclear Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2026,2,11]]},"published-print":{"date-parts":[[2026,6]]},"DOI":"10.2967\/jnumed.125.271976","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T14:20:21Z","timestamp":1773930021000},"page":"871-877","source":"Crossref","is-referenced-by-count":2,"title":["Risk Assessment in Large B-Cell Lymphoma Using Metabolic Tumor Volume: Real-World Data from a Multicenter Cohort of Patients Undergoing CAR T-Cell Therapy"],"prefix":"10.2967","volume":"67","author":[{"given":"Conrad-Amadeus","family":"Voltin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Flossdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Kurch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Winkelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Farolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Beckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Casadei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Kutsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Borchmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Brendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria","family":"Blumenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Fanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kambiz","family":"Rahbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel T.","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Sabri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Drzezga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Dietlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Christian","family":"Reinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang G.","family":"Kunz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jrn C.","family":"Albring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"von Tresckow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Michel","family":"Heger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Gdel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Subklewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Paccagnella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladan","family":"Vucinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Hanoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"2026060105301022000_67.6.871.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115304"},{"key":"2026060105301022000_67.6.871.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30225-4"},{"key":"2026060105301022000_67.6.871.3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03175"},{"key":"2026060105301022000_67.6.871.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"2026060105301022000_67.6.871.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"2026060105301022000_67.6.871.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"2026060105301022000_67.6.871.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133"},{"key":"2026060105301022000_67.6.871.8","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet."},{"key":"2026060105301022000_67.6.871.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.003"},{"key":"2026060105301022000_67.6.871.10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01992"},{"key":"2026060105301022000_67.6.871.11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"2026060105301022000_67.6.871.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"2026060105301022000_67.6.871.13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-038257"},{"key":"2026060105301022000_67.6.871.14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-524108"},{"key":"2026060105301022000_67.6.871.15","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/cam4.1271","article-title":"Simplicity at the cost of predictive accuracy in diffuse large B-cell lymphoma: a critical assessment of the R-IPI, IPI, and NCCN-IPI","volume":"7","author":"Biccler","year":"2018","journal-title":"Cancer Med."},{"key":"2026060105301022000_67.6.871.16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-430389"},{"key":"2026060105301022000_67.6.871.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.06.011"},{"key":"2026060105301022000_67.6.871.18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-616474"},{"key":"2026060105301022000_67.6.871.19","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1182\/blood.2019003526","article-title":"High total metabolic tumor volume at baseline predicts survival independent of response to therapy","volume":"135","author":"Vercellino","year":"2020","journal-title":"Blood."},{"key":"2026060105301022000_67.6.871.20","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.3324\/haematol.2021.278663","article-title":"Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study","volume":"107","author":"Kostakoglu","year":"2022","journal-title":"Haematologica."},{"key":"2026060105301022000_67.6.871.21","doi-asserted-by":"crossref","first-page":"e817","DOI":"10.1097\/HS9.0000000000000817","article-title":"Outcome prediction in patients with large B-cell lymphoma undergoing chimeric antigen receptor T-cell therapy","volume":"7","author":"Voltin","year":"2023","journal-title":"Hemasphere."},{"key":"2026060105301022000_67.6.871.22","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s00259-023-06554-0","article-title":"Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy","volume":"51","author":"Voltin","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026060105301022000_67.6.871.23","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267789"},{"key":"2026060105301022000_67.6.871.24","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1007\/s00259-018-3953-z","article-title":"Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma","volume":"45","author":"Ilyas","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026060105301022000_67.6.871.25","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/MNM.0000000000001324","article-title":"Baseline metabolic tumor volume calculation using different SUV thresholding methods in Hodgkin lymphoma patients: interobserver agreement and reproducibility across software platforms","volume":"42","author":"Tutino","year":"2021","journal-title":"Nucl Med Commun."},{"key":"2026060105301022000_67.6.871.26","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1200\/JCO.21.02063","article-title":"Proposed new dynamic prognostic index for diffuse large B-cell lymphoma: International Metabolic Prognostic Index","volume":"40","author":"Mikhaeel","year":"2022","journal-title":"J Clin Oncol."},{"key":"2026060105301022000_67.6.871.27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13045-024-01540-x","article-title":"Conventional and novel [18F]FDG PET\/CT features as predictors of CAR-T cell therapy outcome in large B-cell lymphoma","volume":"17","author":"Leithner","year":"2024","journal-title":"J Hematol Oncol."},{"key":"2026060105301022000_67.6.871.28","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41408-025-01338-1","article-title":"Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma","volume":"15","author":"Winkelmann","year":"2025","journal-title":"Blood Cancer J."},{"key":"2026060105301022000_67.6.871.29","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002729"},{"key":"2026060105301022000_67.6.871.30","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/ejh.14423","article-title":"Prognostic factors and effect modifiers in patients with relapse or refractory diffuse large B-cell lymphoma after two lines of therapy: a systematic literature and expert clinical review","volume":"115","author":"von Tresckow","year":"2025","journal-title":"Eur J Haematol."},{"key":"2026060105301022000_67.6.871.31","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv."},{"key":"2026060105301022000_67.6.871.32","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1182\/blood.2023021620","article-title":"Axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume","volume":"143","author":"Locke","year":"2024","journal-title":"Blood."},{"key":"2026060105301022000_67.6.871.33","doi-asserted-by":"crossref","first-page":"5083","DOI":"10.1158\/1078-0432.CCR-24-0830","article-title":"Metabolic tumor volume response after bridging therapy determines chimeric antigen receptor T-cell outcomes in large B-cell lymphoma","volume":"30","author":"Hubbeling","year":"2024","journal-title":"Clin Cancer Res."},{"key":"2026060105301022000_67.6.871.34","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3324\/haematol.2021.280550","article-title":"Positron emission tomography-imaging assessment for guiding strategy in patients with relapsed\/refractory large B-cell lymphoma receiving CAR T cells","volume":"108","author":"Galtier","year":"2023","journal-title":"Haematologica."},{"key":"2026060105301022000_67.6.871.35","doi-asserted-by":"crossref","first-page":"7226","DOI":"10.1182\/blood-2024-207843","article-title":"Carmod, an open-label, multicenter, proof of concept, phase II trial, investigating the safety and efficacy of golcadomide in post-CART for patients with relapsed\/refractory high-risk aggressive large B-cell lymphoma","volume":"144","author":"Thieblemont","year":"2024","journal-title":"Blood."},{"key":"2026060105301022000_67.6.871.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.019"},{"key":"2026060105301022000_67.6.871.37","first-page":"3055","article-title":"Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma","volume":"141","author":"Eertink","year":"2023","journal-title":"Blood."},{"key":"2026060105301022000_67.6.871.38","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(75)90597-5"},{"key":"2026060105301022000_67.6.871.39","doi-asserted-by":"publisher","DOI":"10.1172\/JCI45817"},{"key":"2026060105301022000_67.6.871.40","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1007\/s10278-020-00341-1","article-title":"Tumor segmentation and feature extraction from whole-body FDG-PET\/CT using cascaded 2D and 3D convolutional neural networks","volume":"33","author":"Jemaa","year":"2020","journal-title":"J Digit Imaging."},{"key":"2026060105301022000_67.6.871.41","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1007\/s00259-020-05080-7","article-title":"Fully automatic segmentation of diffuse large B cell lymphoma lesions on 3D FDG-PET\/CT for total metabolic tumour volume prediction using a convolutional neural network","volume":"48","author":"Blanc-Durand","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026060105301022000_67.6.871.42","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/hon.3025","article-title":"Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine-treated, interim PET-negative classical Hodgkin lymphoma patients: a radio-genomic study","volume":"40","author":"Durmo","year":"2022","journal-title":"Hematol Oncol."},{"key":"2026060105301022000_67.6.871.43","doi-asserted-by":"crossref","first-page":"39540","DOI":"10.1038\/s41598-025-23159-9","article-title":"Added prognostic value of baseline pre-infusion 18F-FDG PET\/CT in diffuse large B-cell lymphoma patients receiving chimeric antigen receptor T-cell therapy","volume":"15","author":"Mirshahvalad","year":"2025","journal-title":"Sci Rep."},{"key":"2026060105301022000_67.6.871.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.12.005"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.271976","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T20:18:41Z","timestamp":1785269921000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.271976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":44,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,1]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.2967\/jnumed.125.271976"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.271976","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]}}}